The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease
Abstract
BACKGROUND: Complex visual hallucinations (VHs) occur in several pathologic conditions; however, the neural mechanisms underlying these symptoms remain unclear. Although dopamine may have a role, indirect evidence indicates that serotonin may also contribute to the pathogenesis of complex VHs, probably via involvement of the serotonin 2 receptor. OBJECTIVE: To examine for the first time in vivo changes in serotonin 2A receptor neurotransmission among patients having Parkinson disease (PD) with VHs. DESIGN: Case-control study. SETTING: Academic research. PATIENTS: Seven patients having PD with VHs and 7 age-matched patients having PD without VHs were recruited. MAIN OUTCOME MEASURES: We used the selective serotonin 2A receptor ligand setoperone F 18 during positron emission tomography among nondemented patients having PD with VHs. RESULTS: Patients having PD with VHs demonstrate increased serotonin 2A receptor binding in the ventral visual pathway (including the bilateral inferooccipital gyrus, right fusiform gyrus, and inferotemporal cortex) as well as the bilateral dorsolateral prefrontal cortex, medial orbitofrontal cortex, and insula. CONCLUSIONS: This pilot study provides the first in vivo evidence suggesting a role for serotonin 2A receptors in mediating VHs via the ventral visual pathway in PD. Treatment studies should be performed using selective serotonin 2A receptor antagonists, which have important implications for the clinical management of VHs and psychosis in PD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This finding may suggest that this receptor may be facilitating cortical disinhibition, consistent with previous proposals42,43 and studies showing 5-HT2A antagonists reducing psychosis-like symptoms20,42.”
From Deviations in effective connectivity explain different hallucination subtypes in Parkinson's disease psychosis (2026) · cites this paper as [43]
In the citing paper
“exploratory analyses using PET receptor atlases revealed a positive correlation between cortical 5-HT2A receptor distribution and abnormal MMN source activity in PD-VH, consistent with the known role of serotonin in cortical disinhibition53 and psychosis42,43”
From Deviations in effective connectivity explain different hallucination subtypes in Parkinson's disease psychosis (2026) · cites this paper as [43]
Citations
Cites
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
A systematic review of prevalence studies of dementia in Parkinson's disease
Aarsland, D., ZACCAI, J. H., & Brayne, C. (2005) · Movement Disorders · doi:10.1002/mds.20527 · Cited by 1,714
A systematic review of prevalence studies of depression in Parkinson's disease
Reijnders, J. S. A. M., Ehrt, U., Weber, W. E. J., Aarsland, D., & Leentjens, A. F. G. (2008) · Movement Disorders · doi:10.1002/mds.21803 · Cited by 1,239
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Gompel, P. V., Lesage, A. S., Loore, K. D., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model
Gunn, R. N., Lammertsma, A. A., Hume, S. P., & Cunningham, V. J. (1997) · NeuroImage · doi:10.1006/nimg.1997.0303 · Cited by 1,085
Haxby, J., Horwitz, B., Ungerleider, L. G., Maisog, J. M., Pietrini, P., & Grady, C. (1994) · Journal of Neuroscience · doi:10.1523/jneurosci.14-11-06336.1994 · Cited by 1,065
Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors
Fénelon, G. (2000) · Brain · doi:10.1093/brain/123.4.733 · Cited by 1,035
Depression rating scales in Parkinson's disease: Critique and recommendations
Schrag, A. E., Barone, P., Brown, R. G., Leentjens, A. F. G., McDonald, W. M., STARKSTEIN, S. E., Weintraub, D. A., Poewe, W. H., Rascol, O., Sampaio, C., et al. (2007) · Movement Disorders · doi:10.1002/mds.21333 · Cited by 690
Complex visual hallucinations. Clinical and neurobiological insights
Manford, M. (1998) · Brain · doi:10.1093/brain/121.10.1819 · Cited by 682
Allen, P., Larøi, F., McGuire, P. K., & Aleman, A. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.07.012 · Cited by 579 · cited 2×
“38 Unified Parkinson Disease Rating Scale part III score on medication, median (range)d 24 (10-39) 15 (14-20) .”
BackgroundAghajanian, G. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00135-3 · Cited by 371
Visual hallucinations in Parkinson's disease: a review and phenomenological survey
Barnes, J. (2001) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.6.727 · Cited by 341
Zadikoff, C., Fox, S. H., Tang‐Wai, D. F., Thomsen, T. R., de Bie, R. M. A., Wadia, P. M., Miyasaki, J. M., Duff-Canning, S. J., Lang, A. E., & Marras, C. (2007) · Movement Disorders · doi:10.1002/mds.21837 · Cited by 337
Self-citationThe temporal lobe is a target of output from the basal ganglia.
Middleton, F. A., & Strick, P. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8683 · Cited by 301
Functional imaging of human visual recognition
Kanwisher, N., Chun, M. M., McDermott, J. H., & Ledden, P. J. (1996) · Cognitive Brain Research · doi:10.1016/s0926-6410(96)00041-9 · Cited by 250
High-resolution imaging reveals highly selective nonface clusters in the fusiform face area
Kalanit Grill-spector, A., Sayres, R., & Ress, D. B. (2006) · Nature Neuroscience · doi:10.1038/nn1745 · Cited by 218
Altered cortical visual processing in PD with hallucinations
Stebbins, G. T., Goetz, C. G., Carrillo, M. C., Bangen, K. J., Turner, D. A., Glover, G. H., & Gabrieli, J. D. E. (2004) · Neurology · doi:10.1212/01.wnl.0000141853.27081.bd · Cited by 189
Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations
Oishi, N., Udaka, F., Kameyama, M., Sawamoto, N., Hashikawa, K., & Fukuyama, H. (2005) · Neurology · doi:10.1212/01.wnl.0000187116.13370.e0 · Cited by 137
Pharmacology of hallucinations induced by long-term drug therapy
Goetz, C. G., Tanner, C. M., & Klawans, H. L. (1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.4.494 · Cited by 129
Metabolic Alterations in Patients With Parkinson Disease and Visual Hallucinations
Boecker, H., Ceballos-Baumann, A., Volk, D., Conrad, B., Förstl, H., & Häussermann, P. (2007) · Archives of Neurology · doi:10.1001/archneur.64.7.984 · Cited by 123
Blin, J., Pappatà, S., Kiyosawa, M., Crouzel, C., & Baron, J. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90635-8 · Cited by 94
Post‐Synaptic 5‐HT1A and 5‐HT2A Receptors Are Increased in Parkinson's Disease Neocortex
Chen, C., ALDER, J. T., Bray, L., et al. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb10229.x · Cited by 69
Psychotic complications of long-term levodopa treatment of Parkinson's disease
Friedman, A., & Sienkiewicz, J. (1991) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1991.tb04918.x · Cited by 65
Silbersweig, D., & Stern, E. R. (1996) · PubMed · Cited by 63
Fischman, A. J., Bonab, A. A., Babich, J. W., Alpert, N. M., Rauch, S. L., Elmaleh, D. R., Shoup, T. M., Williams, S. A., & Rubin, R. H. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21208-3 · Cited by 59
Maziere, B., Crouzel, C., Venet, M., Stulzaft, O., Sanz, G., Ottaviani, M., Sejourne, C., Pascal, O., & Bisserbe, J. C. (1988) · International Journal of Radiation Applications and Instrumentation Part B Nuclear Medicine and Biology · doi:10.1016/0883-2897(88)90018-9 · Cited by 34
- Self-citation
Cited by
Sorted by citations
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Cummings, J. L., Isaacson, S., Mills, R., Williams, H., Chi‐Burris, K., Corbett, A., Dhall, R., & Ballard, C. G. (2013) · The Lancet · doi:10.1016/s0140-6736(13)62106-6 · Cited by 954
Parkinson's disease: The quintessential neuropsychiatric disorder
Weintraub, D. A., & Burn, D. J. (2011) · Movement Disorders · doi:10.1002/mds.23664 · Cited by 422
The psychosis spectrum in Parkinson disease
ffytche, D. H., Creese, B., Politis, M., Chaudhuri, K. R., Weintraub, D., Ballard, C., & Aarsland, D. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.200 · Cited by 355
Kometer, M., Schmidt, A., Jancke, L., & Vollenweider, F. X. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3007-12.2013 · Cited by 355
Metadata
- Authors
- Ballanger, B., Strafella, A. P., van Eimeren, T., Zurowski, M., Rusjan, P. M., Houle, S., & Fox, S. H.
- Affiliations
- Montreal Neurological Institute and Hospital (CA)
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2010-04-01
- Volume
- 67
- Issue
- 4
- Pages
- 416-21
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2026136738
- Cited by
- 266
- References
- 29
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 8 · 2023: 12 · 2022: 14 · 2021: 17 · 2020: 21 · 2019: 18 · 2018: 19 · 2017: 24 · 2016: 26 · 2015: 8 · 2014: 19 · 2013: 25 · 2012: 7
- FWCI
- 9.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of Neurology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- 5-HT2A receptor, complex visual hallucinations, Parkinson's disease, ventral stream, serotonergic neurotransmission, dopamine, receptor binding imaging, prefrontal cortex, fusiform gyrus, inferotemporal cortex
- MeSH terms
- Aged, Brain, Brain Mapping, Female, Hallucinations, Humans, Male, Middle Aged, Parkinson Disease, Pilot Projects, Pyrimidinones, Serotonin, Serotonin Antagonists, Temporal Lobe, Visual Cortex, Visual Pathways, Case-Control Studies, Receptor, Serotonin, 5-HT2A, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
